PMC:547907 / 590-938 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/547907","sourcedb":"PMC","sourceid":"547907","source_url":"http://www.ncbi.nlm.nih.gov/pmc/547907","text":"Methods\nWe undertook a double-blind, randomised, parallel-group, flexible-dose, placebo-controlled study of quetiapine augmentation in subjects who had responded inadequately to open-label treatment with an SRI for 12 weeks. Following informed consent and screening, forty-two subjects were randomised to either placebo or quetiapine for six weeks.","divisions":[{"label":"Title","span":{"begin":0,"end":7}}],"tracks":[{"project":"NEUROSES","denotations":[{"id":"T34","span":{"begin":108,"end":118},"obj":"CHEBI_8707"},{"id":"T35","span":{"begin":323,"end":333},"obj":"CHEBI_8707"},{"id":"T45","span":{"begin":30,"end":35},"obj":"PATO_0001177"},{"id":"T51","span":{"begin":178,"end":182},"obj":"PATO_0000610"},{"id":"T54","span":{"begin":183,"end":188},"obj":"CHEBI_35209"},{"id":"T57","span":{"begin":58,"end":63},"obj":"CHEBI_24433"},{"id":"T58","span":{"begin":65,"end":73},"obj":"PATO_0001544"}],"attributes":[{"subj":"T34","pred":"source","obj":"NEUROSES"},{"subj":"T35","pred":"source","obj":"NEUROSES"},{"subj":"T45","pred":"source","obj":"NEUROSES"},{"subj":"T51","pred":"source","obj":"NEUROSES"},{"subj":"T54","pred":"source","obj":"NEUROSES"},{"subj":"T57","pred":"source","obj":"NEUROSES"},{"subj":"T58","pred":"source","obj":"NEUROSES"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"NEUROSES","color":"#ecb293","default":true}]}]}}